GLP-1 injection bruising: badge of honor or fixable technique flaw?

What did @morgan.will96 actually say?

Morgan described getting an unusually large bruise after a GLP-1 injection in the fatty area of the arm, noting it persisted for nearly a week. That is a fair, honest account of something real. She asked whether she "chose too much of a muscle" and whether the injection site selection could explain the bruising. She was not making medical claims. She was asking a community question while showing visible evidence on camera.

To her credit, she distinguished this episode from her usual experience, noting she "never bruise[s] or anything" normally. That context matters. A one-off large bruise after an injection is different from chronic bruising, and the fact that she noticed the difference shows reasonable self-awareness. The week-long duration is the part that actually deserves a closer look.

Does the science back this up?

Yes, injection-site bruising after subcutaneous GLP-1 administration is well-documented, and the arm versus abdomen versus thigh location genuinely affects bruising risk. Morgan is not imagining things.

Subcutaneous tissue depth varies considerably by body site and individual. A 2022 review by Frid et al. in Diabetes Technology and Therapeutics confirmed that injection technique, needle length, and tissue depth all influence local adverse events including bruising and hematoma formation. The arm, specifically the posterior triceps area, has shallower subcutaneous fat in many individuals, which increases the chance of inadvertently hitting a small vessel or injecting partially intramuscularly.

A 2019 study by Hirsch et al. in Diabetes Care found that intramuscular injection versus subcutaneous injection significantly increased local reactions, including bruising that lasted longer. A one-week bruise is consistent with a small intramuscular bleed, not necessarily a dangerous event, but worth tracking. Platelet-derived healing of small hematomas typically takes 7 to 14 days depending on size and depth.

What did they get wrong (or right)?

Morgan got more right than wrong. Her instinct that hitting muscle tissue could explain the bruise is actually a reasonable hypothesis. The arm is a trickier site for subcutaneous injection compared to the abdomen, and her question about whether she "chose too much of a muscle" aligns with what injection site research suggests.

Where she is slightly off: calling the fatty area of the arm automatically safe. The posterior upper arm has highly variable subcutaneous thickness. Levin et al. (2011, Diabetes Research and Clinical Practice) found mean subcutaneous depth in the upper arm averaged just 6 to 8mm in many adults, which means standard 4mm to 6mm pen needles can still reach muscle in leaner individuals depending on injection angle.

She does not make any dangerous claims, does not recommend a treatment, and does not catastrophize. That is more than can be said for a lot of health content on TikTok. Her framing as a community question rather than medical advice is appropriate.

What should you actually know?

A large or persistent bruise after a subcutaneous GLP-1 injection deserves attention, not panic. Here is what the evidence suggests matters.

• Injection angle matters. A 45-degree angle with a skin pinch reduces intramuscular injection risk at the arm compared to a straight 90-degree insertion, per the American Diabetes Association injection technique guidelines (2016).
• Rotating sites is not optional. The same-site injections increase local tissue trauma over time. Abdomen, thigh, and arm should all be rotated systematically.
• A bruise persisting beyond 10 to 14 days, or one that is growing rather than fading, warrants a conversation with a prescribing clinician. That is not a panic trigger, it is routine follow-up.
• Blood thinners, NSAIDs, and even high-dose fish oil supplements increase bruising risk at injection sites. If you take any of these, mention it to your provider.
• Compounded GLP-1 formulations and brand-name products are not interchangeable. If you are using a compounded version, concentration and diluent differences can affect injection volume, which can affect tissue response.

Morgan's experience is common enough that it has its own informal name in patient communities. That does not make it normal to ignore. Document it, note the site, and report it to whoever prescribed your medication.